GLP-1 Shortage Ends, Shadow Market for Research Peptides and Compounded Semaglutide Raises Safety Alerts
The FDA’s removal of semaglutide and tirzepatide from shortage lists ends legal compounding by May 2025, but a shadow online market for research-only GLP-1 peptides raises dosing and quality concerns.